» Articles » PMID: 39739621

Tertiary Lymphoid Structures Are Linked to Enhanced Antitumor Immunity and Better Prognosis in Muscle-Invasive Bladder Cancer

Overview
Journal Adv Sci (Weinh)
Date 2024 Dec 31
PMID 39739621
Authors
Affiliations
Soon will be listed here.
Abstract

The prognosis for muscle-invasive bladder cancer (MIBC) remains poor, and reliable prognostic markers have yet to be identified. Tertiary lymphoid structures (TLS) have been associated with favorable outcomes in certain cancers. However, the relationship between TLS and MIBC remains unclear. A multi-omics approach is utilized, leveraging single-cell RNA sequencing, spatial transcriptomics, bulk RNA sequencing, and immunohistochemistry, to investigate the roles of B cells and TLS in MIBC. These findings indicate that elevated levels of B cells and TLS correlate with improved prognoses in patients with MIBC, aligning with the robust antitumor immune responses observed in the TLS region. From a mechanistic perspective, CXCL13 serves as a critical cytokine for TLS formation in MIBC, primarily secreted by clonally expanded CXCL13+ T cells. This cytokine interacts with the CXCR5 receptor on NR4A2+ B cells, promoting TLS development. Plasma cells arising within the TLS microenvironment predominantly produce the IGHG antibody, potentially enhancing the phagocytic capabilities of C1QC+ macrophages. From an application standpoint, a TLS-specific gene signature is developed that effectively predicts outcomes in MIBC and other cancers. This study highlights the prognostic potential of TLS in MIBC and reveals immune mechanisms, offering insights for personalized treatment strategies.

Citing Articles

Sepsis-induced cardiac dysfunction: mitochondria and energy metabolism.

Yu X, Gao J, Zhang C Intensive Care Med Exp. 2025; 13(1):20.

PMID: 39966268 PMC: 11836259. DOI: 10.1186/s40635-025-00728-w.


Tertiary Lymphoid Structures are Linked to Enhanced Antitumor Immunity and Better Prognosis in Muscle-Invasive Bladder Cancer.

Lin J, Jiang S, Chen B, Du Y, Qin C, Song Y Adv Sci (Weinh). 2024; 12(7):e2410998.

PMID: 39739621 PMC: 11831474. DOI: 10.1002/advs.202410998.

References
1.
Helmink B, Reddy S, Gao J, Zhang S, Basar R, Thakur R . B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020; 577(7791):549-555. PMC: 8762581. DOI: 10.1038/s41586-019-1922-8. View

2.
Banchereau R, Chitre A, Scherl A, Wu T, Patil N, De Almeida P . Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade. J Immunother Cancer. 2021; 9(4). PMC: 8032254. DOI: 10.1136/jitc-2020-002231. View

3.
Ukita M, Hamanishi J, Yoshitomi H, Yamanoi K, Takamatsu S, Ueda A . CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. JCI Insight. 2022; 7(12). PMC: 9309049. DOI: 10.1172/jci.insight.157215. View

4.
Coppola D, Nebozhyn M, Khalil F, Dai H, Yeatman T, Loboda A . Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol. 2011; 179(1):37-45. PMC: 3123872. DOI: 10.1016/j.ajpath.2011.03.007. View

5.
Rebouissou S, Bernard-Pierrot I, De Reynies A, Lepage M, Krucker C, Chapeaublanc E . EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med. 2014; 6(244):244ra91. DOI: 10.1126/scitranslmed.3008970. View